E
Editas Medicine
Cambridge, United States
Founded 2013 NASDAQ: EDIT
Gene Therapy Delivery DNA Nanotechnology Cell Therapy Nano Nano-Bio Protein Engineering Nanosequencing
About
CRISPR-based medicines for genetic diseases including eye disorders
Company Details
- Type
- public
- Employees
- 400+
- Funding
- Public
Key Products
- EDIT-101
- Gene Editing Therapies